TY - JOUR
T1 - Correction to
T2 - 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines (Circulation (2026), (153), (17), (10.1161/CIR.0000000000001423))
AU - Blumenthal, Roger S.
AU - Morris, Pamela B.
AU - Gaudino, Mario
AU - Johnson, Heather M.
AU - Anderson, Timothy S.
AU - Bittner, Vera A.
AU - Blankstein, Ron
AU - Brewer, La Princess C.
AU - Cho, Leslie
AU - de Ferranti, Sarah D.
AU - Gianos, Eugenia
AU - Gluckman, Ty J.
AU - Gradney, SPC; Kristen F.
AU - Isiadinso, Ijeoma
AU - Lloyd-Jones, Donald M.
AU - Marrs, Joel C.
AU - Martin, Seth S.
AU - McLain, Kellie H.
AU - Mehta, Laxmi S.
AU - Mora, Samia
AU - Mulugeta, Wudeneh M.
AU - Natarajan, Pradeep
AU - Navar, Ann Marie
AU - Orringer, Carl E.
AU - Polonsky, Tamar S.
AU - Reynolds, Harmony R.
AU - Saseen, Joseph J.
AU - Shapiro, Michael D.
AU - Soffer, Daniel E.
AU - Tynes, Sheila A.
AU - Villavaso, Chloé D.
AU - Virani, Salim S.
AU - Wilkins, John T.
N1 - Publisher Copyright:
© 2026 Lippincott Williams & Wilkins
PY - 2026/9/8
Y1 - 2026/9/8
N2 - In the article by Blumenthal et al, “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines,” which published ahead of print on Friday, March 13, 2026, and appeared in the April 28, 2026, issue of the journal (Circulation. 2026;153:e1154–e1276. DOI: 10.1161/CIR.0000000000001423), corrections are needed. On page e1177, in Table 5, in the “Bile acid sequestrants” class, the following corrections are needed: The dose for Colesevelam was “3.75 mg.” It has been updated to “3.75 g.” The dosing frequency for Cholestyramine was “Once or twice daily.” It has been updated to “In 1 to 4 equally divided doses.” The dosing frequency for Colesevelam was “Once or twice daily.” It has been updated to “In 1 or 2 equally divided doses.” The dosing frequency for Colestipol was “Once or multiple times daily.” It has been updated to “In 1 or 2 equally divided doses.” These corrections have been made to the current online version of the article, which is available at: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423
AB - In the article by Blumenthal et al, “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines,” which published ahead of print on Friday, March 13, 2026, and appeared in the April 28, 2026, issue of the journal (Circulation. 2026;153:e1154–e1276. DOI: 10.1161/CIR.0000000000001423), corrections are needed. On page e1177, in Table 5, in the “Bile acid sequestrants” class, the following corrections are needed: The dose for Colesevelam was “3.75 mg.” It has been updated to “3.75 g.” The dosing frequency for Cholestyramine was “Once or twice daily.” It has been updated to “In 1 to 4 equally divided doses.” The dosing frequency for Colesevelam was “Once or twice daily.” It has been updated to “In 1 or 2 equally divided doses.” The dosing frequency for Colestipol was “Once or multiple times daily.” It has been updated to “In 1 or 2 equally divided doses.” These corrections have been made to the current online version of the article, which is available at: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423
UR - https://www.scopus.com/pages/publications/105049624299
U2 - 10.1161/CIR.0000000000001475
DO - 10.1161/CIR.0000000000001475
M3 - Comment/debate
C2 - 42709919
AN - SCOPUS:105049624299
SN - 0009-7322
VL - 154
SP - e393-e393
JO - Circulation
JF - Circulation
IS - 10
ER -